Latest Hotspot

US health authorities fast-track review of Patritumab Deruxtecan for certain advanced EGFR-mutant Non-Small Cell Lung Cancer post-initial therapy

2 January 2024
3 min read

Daiichi Sankyo and Merck have declared that the Biologics License Application for patritumab deruxtecan (HER3-DXd) has garnered Priority Review status from the U.S. Food and Drug Administration. This application pertains to the use of this therapeutic agent in the care of adults who are dealing with either locally advanced or metastatic non-small cell lung cancer marked by EGFR mutations, and who have already undergone at least two systemic treatment regimens.

👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

The target action date set by the FDA under the Prescription Drug User Fee Act for their assessment decision is scheduled for the 26th of June, 2024. Following the designation of Breakthrough Therapy received from the FDA in December 2021, the application now has the benefit of a Priority Review status. 

The FDA prioritizes the review of drug applications that could potentially represent substantial advancements in treatment compared to existing therapies, either through showing an improvement in safety or effectiveness, averting severe health issues, or contributing to better adherence to treatments by patients.

The Biologics License Application (BLA) for patritumab deruxtecan is undergoing examination as part of the FDA’s Real-Time Oncology Review (RTOR) program, which aims to expedite the process of delivering new and effective anti-cancer drugs to patients in need. The RTOR framework permits the FDA to begin evaluating certain sections of a drug’s application ahead of the full package being submitted.

Patritumab deruxtecan, which is being co-developed and marketed by Daiichi Sankyo in partnership with Merck, is an innovative potential leading agent targeting HER3 with a DXd antibody-drug conjugate format. This therapy was originally identified by Daiichi Sankyo.

Data underpinning the BLA include findings from the central assessment of the HERTHENA-Lung01 Phase 2 study, alongside outcomes showcased at the IASLC World Conference on Lung Cancer in 2023. These findings were also concurrently released in the Journal of Clinical Oncology.

Commenting on the FDA’s prioritized handling of the BLA, Ken Takeshita, MD, who is the Global Head of R&D at Daiichi Sankyo, mentioned, “The expedited review by the FDA underscores the compelling nature of the data emerging from the HERTHENA-Lung01 study, and it highlights the urgency in delivering novel therapeutic alternatives to individuals battling advanced stages or metastatic instances of EGFR-mutated non-small cell lung cancer after undergoing two or more systemic treatment rounds.”

👇Please click on the picture link below for free registration or login directly if you have freemium accounts, you can browse the latest research progress on drugs, indications, organizations, clinical trials, clinical results, and drug patents related to this target.

图形用户界面, 应用程序

中度可信度描述已自动生成

According to the data provided by the Synapse Database, As of December 30, 2023, there are 1 investigational drugs for the HER3 and TOP1 target, including 13 indications, 8 R&D institutions involved, with related clinical trials reaching 29, and as many as 159 patents.

Patritumab deruxtecan was granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration in December 2021 for the treatment of patients with EGFR-mutated locally advanced or metastatic NSCLC with disease progression on or after treatment with a third-generation TKI and platinum-based therapies.

图形用户界面, 文本

描述已自动生成

Histamine receptor antagonists: What They Are and How to Stay Informed About Recent Advances
Histamine receptor antagonists: What They Are and How to Stay Informed About Recent Advances
2 January 2024
Histamine receptor antagonists are drugs that block histamine action, relieving allergic reactions.
Read →
CD20-Targeted Antibody, Rituxan, Sanctioned for Prevention and Therapy of Organ Rejection Due to Antibodies
Latest Hotspot
3 min read
CD20-Targeted Antibody, Rituxan, Sanctioned for Prevention and Therapy of Organ Rejection Due to Antibodies
2 January 2024
Zenyaku Kogyo Co., Ltd. and Chugai Pharmaceutical Co., Ltd. have announced obtaining approval from Japan's Ministry of Health, Labour and Welfare to commercially distribute Rituxan®.
Read →
What are the effects of ubiquitination on protein degradation?
"What" Series
2 min read
What are the effects of ubiquitination on protein degradation?
2 January 2024
Ubiquitination is a process that involves adding a protein called ubiquitin to a substrate protein.
Read →
Demystifying H2 receptor antagonists: A Comprehensive Guide and How to Keep Up with the Latest Developments
Demystifying H2 receptor antagonists: A Comprehensive Guide and How to Keep Up with the Latest Developments
2 January 2024
H2 receptor antagonists are drugs that inhibit histamine action in the stomach, reducing acid production.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.